A Multicenter, Randomized, Double-blind, Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19
Latest Information Update: 23 Jan 2024
At a glance
- Drugs Ritonavir+simnotrelvir (Primary) ; Ritonavir
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Simcere Pharmaceutical Group
Most Recent Events
- 18 Jan 2024 Primary endpoint has been met. (Time to sustained recovery of 11 COVID-19 symptoms)
- 18 Jan 2024 Results published in the New England Journal of Medicine
- 09 May 2023 Last checked against ClinicalTrials.gov: US National Institutes of Health record.